Correlation Engine 2.0
Clear Search sequence regions


  • antigens (1)
  • control group (2)
  • curcumin (8)
  • dyspepsia (10)
  • help (1)
  • hong kong (1)
  • humans (1)
  • patients (3)
  • rome (1)
  • Sizes of these terms reflect their relevance to your search.

    BackgroundFunctional dyspepsia is the main cause of upper abdominal discomfort affecting 5-10% of the world population. Despite various therapeutic approaches, up to 50% of patients with functional dyspepsia seek alternative treatments. In the present study we evaluated the effect of curcumin supplementation along with famotidine therapy on severity of functional dyspepsia. A total of 75 patients with functional dyspepsia according to Rome III criteria were allocated into intervention (N = 39) or control (N = 36) groups. The intervention group was treated with a combination of 500 mg curcumin and 40 mg famotidine daily for 1 month. The control group received placebo and 40 mg famotidine. Severity of dyspepsia symptoms was determined using the Hong Kong questionnaire at baseline, after the 1 month treatment and after a 1 month follow-up. The presence of H. pylori antigens in the stool samples was also investigated in all subjects. No significant difference was observed between intervention and control groups in biochemical indices, severity of dyspepsia and rate of H. pylori infection. A significant decrease was observed in severity of dyspepsia (p < 0.001) and rate of H. pylori infection (p = 0.004) immediately after the treatment and follow-up in the curcumin intervention group. This study indicated that curcumin therapy could be a favorable supplementation in the symptom management of functional dyspepsia. Moreover, curcumin could help efficient eradication of H. pylori in these patients.

    Citation

    Yunes Panahi, Ashraf Karbasi, Ghasem Valizadegan, Nayyereh Ostadzadeh, Sara Saffar Soflaei, Tannaz Jamialahmadi, Muhammed Majeed, Amirhossein Sahebkar. Effect of Curcumin on Severity of Functional Dyspepsia: a Triple Blinded Clinical Trial. Advances in experimental medicine and biology. 2021;1308:119-126

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33861441

    View Full Text